Hundreds of Abilify patients have developed severe impulse-control disorders after taking the potent antipsychotic drug.
- Compulsive gambling, eating, shopping and sex
- 500+ personal injury lawsuits
- Consolidated in Florida MDL
Did you or a loved one develop compulsive behaviors after using Abilify? Take action now. Some Abilify patients may be entitled to significant financial compensation, but time is limited.
Contact our experienced attorneys now to learn more in a free consultation.
Abilify’s significant risks have threatened hundreds, if not thousands, of families.
"The Attorneys You Need" Laurence and his team are prepared to fight for you.
Did you see a television commercial about Abilify? A number of law firms have begun airing these ads, usually during local broadcasts, to inform patients about a growing litigation that involves the popular antipsychotic medication.
Commercials Focus On Abilify Gambling Litigation
In their commercials, attorneys say Abilify has been linked to an increased risk for compulsive gambling. TV ads often note that some patients have lost over $50,000 to gambling compulsions allegedly caused by Abilify.
Our Lawyers want to help
That’s all true, but the commercial you saw probably left out some very important details. To begin with, Abilify hasn’t just been linked to compulsive gambling. It’s also at the root, according to new lawsuits, of other forms of impulse-control disorder. In medical journals and reports to the US Food & Drug Administration, Abilify patients say they developed compulsions to overeat, shop and have sex. So while most plaintiffs claim to have experienced a problem with gambling, the issue appears to go far beyond that.
500+ Abilify Lawsuits In Florida MDL
None of the lawsuit commercials on TV say anything about the nature of this litigation. Today, nearly 600 Abilify lawsuits are pending in the US District Court for the Northern District of Florida. The cases, because they all share similar allegations, have been consolidated as a federal Multi-District Litigation. That means the claims of individual plaintiffs will move through pre-trial proceedings, like discovery, as a group.
This Isn’t A Class Action
This form of consolidation is much more efficient, both for plaintiffs, the attorneys involved and the defendant pharmaceutical companies. It’s not a class action, though. Every patient will retain full control over their own legal action, including the power to make crucial decisions about settlement and trial. No one has to represent anyone else in court. But they can work together to develop the strongest case.
Otsuka Pharmaceutical & Bristol-Myers Squibb
The patients behind these lawsuits are suing two companies, a Japanese pharmaceutical manufacturer, Otsuka Pharmaceutical Co., and American manufacturer Bristol-Myers Squibb. Otsuka “discovered” and developed aripiprazole, Abilify’s active ingredient, for the healthcare market, securing FDA approval in 2002. Bristol-Myers Squibb got involved later, contracting with Otsuka to take over some, but not all, of the marketing efforts in the United States.
Both companies, plaintiffs say, played a significant role in presenting Abilify to the public and medical community. This is where the allegations of misconduct come in. In their lawsuits, patients accuse the two pharmaceutical companies of concealing Abilify’s risks from the American market.
Compulsive Gambling Warnings Came Late, Lawsuits Claim
Abilify’s product labeling only began to mention a risk for compulsive gambling in 2016. Things were very different overseas. Abilify has carried a warning about pathological gambling in Europe since 2012. A similar warning appeared on the drug’s Canadian labeling in 2015.
US consumers, on the other hand, only got a notice about the problem in January 2016, when Abilify’s manufacturers added a brief mention of “pathological gambling” to the 42nd page of the drug’s prescribing information packet. Unsurprisingly, few people saw the new warning. So, in May 2015, the US Food & Drug Administration took matters into its own hands.
FDA Steps In
That brief mention of pathological gambling added by the manufacturers ? It didn’t “entirely reflect the nature of the impulse-control risk,” FDA researchers wrote. In a rare move, the FDA put increased warnings on the Abilify label of its own accord, informing patients and doctors that the drug had been linked to “compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex.” Now, Abilify patients can’t help but ask why they didn’t receive a stronger warning earlier.
Learn More In A Free Consultation
Did you or a loved one experience compulsive behaviors after being prescribed Abilify? You may be eligible to pursue significant financial compensation. Compulsive gambling, overeating and other impulse-control problems can steal time and money, along with any sense of control over your life. Many Abilify patients say they gambled away over $75,000, threatening their financial security and the lives of their loved ones. Our experienced personal injury attorneys can help. To learn more about your legal options, contact our lawyers today for a free consultation.